Specific pathogen free kittens werevaccinated with an unattenuated field isolate of canine coronavirus (ccv) either by aerosol or subcutaneously, and received boosting vaccinations four weeks later. Aerosolisation elicited a homologous virus-neutralising (VN) antibody response that increased steadily over a fourweek period and levelled off one to two weeks after revaccination. The initial aerosolised dose produced an asymptomatic infection with excretion of eev from the oropharynx up to eight days after vaccination; virus shedding was not detected, however, after the second inoculation. Cats vaccinated subcutaneously developed low VN antibody titres after the first eev dose and experienced a strong anamnestic response after the second dose. Neutrallsing antibody titres then levelled off one to two weeks after revaccination at mean values somewhat lower than in cats vaccinated by aerosol. eev was not isolated from the oropharynx after either subcutaneous dose. Four weeks after eev boosting inoculations, vaccinated cats and sham-vaccinated control cats were divided into three subgroups~nd challenged by aerosol with.the virulent ucm strain of feline infectious peritonitis virus (FIPV ucm) at three different dosage levels. Five of six cats (including sham-vaccinated controls) given the lowest challenge dose showed no signs of disease, while all other cats developed lesions typical of feline infectious peritonitis (FIP) . The five surviving cats developed FIP after subsequent challenge with a fivefold higher dose of F1PV. Thus heterotypic vaccination of cats with eev did not provide effective protection against FIPV challenge. FELINE infectious peritonitis virus (FlPV), a member of the family Coronaviridae, is an important pathogen of domestic and exotic cats (Barlough and Weiss 1983 , Barlough and Stoddart 1986 ,Scott 1986 , Pedersen 1987 . It is the causative agent of a lethal, immunologically mediated vasculitis, feline infectious ·Present address: Oklahoma Animal Disease Diagnostic Laboratory, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma 74078, USA peritonitis (FlP), characterised by fibrinous peritonitis or pleuritis and formation of disseminated pyogranulomas. Current therapies, usually consisting of corticosteroids or other more potent cytoreductive drugs, are only palliative in nature and in most instances are ineffective at halting the relentlessly progressive course of the disease.
A safe and effective FIP vaccine has not yet been developed. Experiments thus far reported using various viruses within the FIPV antigenic cluster (Pedersen et al 1978) have not been successful in conferring uniformly protective immunity (Toma et al 1979 , Woods and Pedersen 1979 , Pedersen et al 1981 , 1984 , Pedersen and Black 1983 , Barlough et al 1984b , Pedersen and floyd 1985 . Paradoxically, because of the immunopathological nature of the disease, vaccination with some feline coronaviruses has actually predisposed cats to the development of FIP and produced a more rapid and fulminating disease after FlPV challenge. Heterotypic vaccination using cross reactive coronaviruses (transmissible gastroenteritis virus [TGEV) of pigs, canine coronavirus lccvl, d'r human coronavirus 229E) has neither sensitised nor protected cats in most experiments. The mechanisms of sensitisation and immunity in FlP are incompletely understood at present, but it may be supposed that, as with many virus infections, a properly balanced cell-mediated immune response involving T lymphocytes, natural killer cells and activated macrophages is essential for effective host resistance.
In an earlier pilot study (Barlough et al1984b) , the authors demonstrated that ccv is capable of infecting cats and that antibodies elicited by multiple daily .oronasal doses of the virus could cross react in a commercially available coronavirus antibody test using TGEV as target antigen. Vaccination with ccv produced no clinical signs of infection, did not result in excretion of detectable virus in faeces, and did not protect cats against FIPV challenge. The number of cats used in this first study was small, however, and only a large challenge dose of FIPV was investigated. A larger study using a greater number of cats was then undertaken, vaccinating by aerosol and subcutaneous routes, assaying for virus excretion from the oropharynx and challenging with three different doses of FIPV, all of which were smal1erthan the dose used in the pilot study. The results of this more comprehensive vaccine trial are the subject of the present communication.
Materials and methods

Animals
Eighteen 14-week-old specific pathogen free kittens (nine female, nine male) were purchased from Liberty Laboratories and housed singly in negativepressure fibreglass isolation cages that were specially equipped for maximal air exchange. Cats from this commercial breeding colony are free of serum coronavirus antibodies, feline' leukaemia virus and other feline virus infections, but are vaccinated against feline panleucopenia with an inactivated vaccine. Strict isolation procedures were fol1owed in the care of animals throughout the experiment and, to minimise the possibility of virus contamination between groups, vaccinated and sham-vaccinated control cats were cared for on alternate days. Two adult coronavirus antibody-negative cats obtained previously from the same breeding colony were used as sentinel room controls.
Viruses and cells
A cloned stock of the Karbatsch isolate of ccv was propagated in canine A-72 cel1s as described previously (Barlough et al1983b, 1984b . This virus was originally isolated in March 1978from faeces of a dog with enteritis (L. E. Carmichael, Cornel1 University, personal communication). A virulent strain of FlPV (FIPV UCDI) (Pedersen 1976 ) was prepared as a liver homogenate (50 per cent concentration in culture medium) after passage through specific pathogen free cats. Homogenates were centrifuged at 200 g for 10 minutes at 4°C and the supernatants pooled and stored at -70°C for use as challenge inocula. Previous similar preparations (Weiss 1981) were determined to contain approximately 100cat infective doses (10100) ml: I. Four concentrations of homogenate (25 per cent, 5 per cent, 2'5 per cent and 0·5 per cent, in Leibovitz's L-15 medium [Gibcol) were used in this study.
Serological assays
Virus neutralisation (VN) tests using ccv (Karbatsch) were performed essentially as described (Barlough et al 1983b) , with only minor modifications. Coronavirus antibody titres were also determined in a computer-assisted, kinetics-based enzymelinked immunosorbent assay (KELA), using TGEV as antigen, as described previously (Barlough et al 1983a (Barlough et al , 1987 .
Virus isolation
Oropharyngeal swab samples were eluted individuallyin 1·0 ml of L-I5 medium and stored at -70°C. Upon thawing, 0'1 ml of each sample was added to quadruplicate wel1s of A-72 cel1s grown in 24-wel1 plates (Costar). Cel1 monolayers were observed for seven days for development of the characteristic syncytial cytopathic effect of ccv (Karbatsch) (Barlough et aI1983b). Cytopathic effect was usual1y evident within two days of inoculation of cel1s with positive samples.
Experimental design
Specific pathogen free cats were initial1y divided into five experimental groups as shown in Table I . On days 0 and 27, cats in groups 1 to 4 were vaccinated with either ccv (vaccinated cats) or uninfected A-72 cel1 culture fluid supernatant (sham-vaccinated control cats). Cats in group I were each given 5 ml of A-72 culture supernatant containing 2 X 10 7 TC1OS0 CCV by an aerosolisation procedure described previously Scott 1981, Barlough et al 1984b) . Briefly, cats were confined within a plastic anaesthetic chamber (Searles Industries), and aerosolisation was performed with a fine-particle (under O·5 /Am) nebuliser (Hoechst-Roussel Pharmaceuticals) at 20 psi for 10 minutes. Cats remained in the nebulised fog for an additional 10 minutes before removal from the chamber. Cats in group 2 were inoculated by a single subcutaneous injection in the cervical region with 2 ml of culture supernatant containing 8 x 1()6TC1OS0 CCV. Cats in groups 3 and 4 were sham-vaccinated with uninfected culture supernatant by the aerosol and subcutaneous rqptes, respectively. Cats in group 5 were maintained as sentinel room controls and were not exposed to CCV, FIPV or uninfected A-72 culture supernatants.
On day 55, four weeks after the second vaccination, cats in groups 1 to 4 were challenged with FIPV UCDI by aerosol according to the scheme illustrated in Table 1 . Three concentrations of liver homogenate were employed (25 per cent, 5 per cent and O·5 per cent) and aerosolisation was performed as described for vaccination, using 5 ml of the appropriate FIPV preparation. The amount of virus delivered was calculated to be 250, 50 or 5 10100, respectively, for each of the three homogenate concentrations. Cats that survived the lowest FlPV challenge dose were rechallenged on day 125 (10 weeks' after the first chal1enge) with a 2· 5 per cent liver homogenate preparation containing approximately 25 10100.
Al1 cats were monitored daily for clinical signs, and For the subgroup C cats that survived, the time interval between the first FIPV challenge and the second, lethal challenge is not shown, so that all data after challenge represent synchronised responses to FIPV. Aerosol CCV = group 1; subcutaneous CCV = group 2; sham-vaccinated controls = groups 3 and 4; sentinel room controls (group 5) not shown oropharyngeal swab samples for ccv isolation were collected at variable intervals (ranging from once daily to once weekly) during the vaccination portion of the experiment. Blood samples for coronavirus antibody detection were obtained once weekly by jugular venipuncture. Cats given FIPV were humanely killed when they became moribund by intracardiac administration of a euthanasia solution (T-6I R , National Laboratories), after initial anaesthesia with ketamine hydrochloride, and tissues were collected for histopathological examination in order to confirm the clinical diagnosis. Clinical observation of room control cats (group 5) was continued for several months after termination of the experiment.
Statistical methods
Differences in mean survival time after lethal FIPV challenge were tested for significance by the Mann-Whitney rank sum method for unpaired measurements (Snedecor and Cochran 1980) .
Results
. Response to challenge (Table I) All cats given the two larger doses of FIPV (subgroups A and B) developed clinical signs of FIP; the diagnosis was confirmed by histopathological examination of tissues after death. Five of six cats given the smallest challenge dose (0' 5 per cent liver homogenate, subgroup C) remained healthy while the sixth, which had been vaccinated with ccv sub-signs of FIP and remained healthy throughout the course of the experiment. C. A. Stoddart, J. E. Barlough, C. A. Baldwin, F. W. Scott developed extremely low VN titres that were first detected two weeks after vaccination. These tit res rose only marginally during the succeeding two weeks but were boosted to high levels by the second vaccination, reaching a plateau at a mean value of 1/125. Neutralising antibody titres in individual cats remained relatively stable after FIPV challenge. Shamvaccinated cats (groups 3 and 4) were consistently negative in ccv VN tests I before FIPV challenge. Extremely low levels of heterotypic VN antibody were detected terminally in only the two subgroup C cats after the second, lethal challenge.
Cross-reacting antibodies to TGEV were not detected in any cat until after lethal FIPV challenge (Fig 2) . A rapid and dramatic rise in KELA titres occurred in aerosol-vaccinated cats (group I) after challenge, perhaps reflecting the production of nonneutralising antibody (Barlough et aI1984b) . The two cats that survived the lowest FIPV challenge dose (subgroup C) did not develop KELA titres until after the second,lethal challenge. Antibodies to TGEV were detected in only two subcutaneously vaccinated cats (group 2) after challenge (the one surviving subgroup C cat developed KELA titres only after the second, lethal FIPV challenge). Several cats given subcutaneous inoculations developed elevated background reactivity in their serum as detected by KELA; such reactivity has been associated previously with humoral immune responses to extraneous, noncoronaviral components of cell culture medium (Barlough et al 1984a) . All sham-vaccinated cats (groups 3 and 4) remained negative by KELA after FIPV challenge.
Sentinel room control cats were seronegative in both assays throughout the course of the experiment (data not shown). 
Serological responses
Virus-neutralising antibody titres against ccv after vaccination and challenge are shown in Fig 1. Cats vaccinated with ccv by aerosol (group I) developed VN antibody titres that were first detected two weeks after vaccination and that rose steadily during the succeeding two weeks. A further but less dramatic increase occurred after the second ccv vaccination, with tit res levelling off at a mean value of 1/260. A heterotypic VN anamnestic response was not seen after FIPV challenge; instead, titre levels in individual cats remained stable until their death ,. (Table 2) . All four cats from the aerosol group shed virus from the oropharynx up to eight days after the first vaccination; shedding did not occur, however, after the second ccv vaccination. The two cats in the subcutaneous group did not shed detectable amounts of ccv after either vaccination.
Discussion
The recognised antigenic cross reactivity between FIPV and ccv originally prompted the authors to examine the potential of CCV for protection of cats against virulent FIPV challenge. In an earlier pilot study (Barlough et al I984b) , two cats were vaccinated with ccv (Karbatsch) oronasally and challenged with a large dose (approximately 1000 101(0) of FIPV UCDl by aerosol. Both cats succumbed to FIP with a mean survival time of 25' 5 ± 2' 5 days, and shamvaccinated control cats experienced a similar disease course (mean survival time 23' 5 ± I· 5 days). Feline coronavirus antibody-sensitised control cats, however, died 8· 5 ± O·5 days after F1PV challenge (P<0·005). It was therefore concluded that vaccination of cats with ccv did not sensitise them to develop accelerated FIP after subsequent FIPV exposure. The expanded study reported here was performed to evaluate more fully the potential of ccv as a heterotypic immunogen for FIP. Cats were vaccinated with ccv by aerosol to induce a potentially more protective mucosal immunity against aerosol challenge than the oronasal vaccination used in the pilot study. In addition, lower, graded challenge doses (5 to (250 101(0) of FIPV were used. It was not possible, however, to demonstrate convincing protection against even the lowest FIPV challenge dose; thus it appears that vaccination of cats with ccv cannot confer protection against FIPV.
Although it initially seemed that five of six cats receiving the lowest FIPV dose (subgroup C) had resisted challenge, a second challenge with 25 10100 of virus showed that they were not immune. The most likely explanation is that these five cats did not receive an infective dose of FIPV during the initial aerosol challenge. This view is supported by three observations: (i) the characteristic KELA response in the ccvvaccinated cats and the terminal ccv VN response ·in the sham-vaccinated cats, both of which appeared only after the second, lethal FlPV challenge dose; (ii) the evolution of immune responses in the surviving sham-vaccinated cats, which was primary rather than anamnestic; and (iii) the absence of sensitisation in all five cats, as indicated by mean survival times (infection with FIPV UCDI by the initial challenge dose would have sensitised the cats so that after the second FlPV UCDI challenge the more rapid and fulminating FIP disease course would have ensued (Barlough et al I984b) .
The present experiment documents ccv shedding from cats for the first time. Cats vaccinated by aerosol were shown to excrete ccv from the oropharynx for up to eight days after inoculation; following revaccination with ccv, however, virus shedding did not occur, suggesting that the cats were immunised against CCV. Unfortunately this immunity was not heterotypic and did not extend to FIPV.
The VN antibody response elicited by the first ccv aerosol vaccination increased steadily over the succeeding four weeks in a manner suggesting in vivo amplification of the inoculated dose ( Fig I) (Mims 1982) .This result also was obtained in the earlier pilot study and is now further supported by the pattern of ccv excretion from the oropharynx ( Table 2) . Considered together with the apparent absence of shedding following the boosting ccv vaccination, it would appear that limited replication of ccv occurred in the aerosol-vaccinated cats and that these cats were then to some degree immunised against subsequent ccv infection. By contrast, subcutaneous inoculation of cats with ccv elicited an initial, low level VN response that was boosted considerably by revaccination, data indicative of an anamnestic response to an inert immunogen (Mims 1982) and suggesting little or no replication of ccv in cats vaccinated subcutaneously.
Unlike the authors' earlier study, ccv-vaccination did not elicit cross-reacting antibodies to TGEV detectable by KELA. In the previous experiment, however, cats developed KELA titres only after repeated daily oronasal administration of CCV, not after the initial two doses. As descr;Jbed previously (Barlough et al 1984b) , . this phenomenon is attributed to two factors. First, administration Qf low doses of coronaviruses can result in production of only neutralising antibodies directed against the viral peplomer while higher doses can result in additional antibodies to non-peplomer determinants that are non-neutralising. Second, neutralising anti-peplomer antibody is detected by VN, but perhaps not by KELA due to loss or antigenic alteration of the fragile peplomers during TGEV antigen preparation. Cats in the present experiment may not have been given a dose of ccv sufficient to produce detectable non-peplomer anti-. body, and thus remained negative by KELA until after lethal FlPV challenge. The dramatic anamnestic response in the aerosolvaccinated cats suggests some priming of the immune response by non-peplomer determinants before challenger, the meagre KELA response of subcutaneously vaccinated' cats after challenge may reflect a smaller degree of priming attributable to little or no ccv replication. As in the pilot study. shamvaccinated cats remained negative by KELA even after lethal FIPV challenge. The authors have often encountered the absence of a KELA response against TGEV in coronavirus-naive cats after experimental FIPV challenge, and it is probably due to a combination of the induction of a primary rather than anamnestic immune response, the swiftly fatal experimental disease course, immune complex formation and lesser sensitivity of the heterologous assay.
This study confirms the earlier findings that ccvvaccinated cats are not sensitised to FIPV. Previous studies have shown that some cats with pre-existing coronavirus antibody, when challenged with FIPV, develop a more rapid and fulminating form of the disease than do seronegative cats similarly challenged (Toma et al1979, Pedersen and Boyle 1980 , Weiss et a11980, Pedersen et al1981, 1984 , Weiss 1981 , Weiss and Scott 1981 , Pedersen and Black 1983 ,Barlough et al 1984b , Pedersen and floyd 1985 . Feline coronavirus strains appear to predominate as sensitising coronaviruses; neither TGEV, human coronavirus 229E nor ccv has produced significant sensitisation in experiments reported thus far. Sensitisation appears to be coronavirus strain-specific and dependent on the identity not only of the sensitisingvirus but also of the challenge strain. The sensitisation phenomenon has proved to be one of the major impediments to the development of a safe and effective FIP vaccine; thus it was hoped that a non-sensitising, cross-reactive coronavirus such as ccv might be able to provide immunity without sensitisation. To date, however, this strategy has not met with success.
The mechanisms governing immunity in FIP remain largely unidentified. Results from work carried out over the past decade suggest, however, that the humoral immune response is probably of minor significance and, when of a sensitising nature, may even be detrimental to the host. In other reports of FIP immunisation attempts and in more recent experiments performed in this laboratory, vaccinated cats have responded unpredictably and idiosyncratically to virulent FIPV challenge. Protection has often been an all-or-nothing phenomenon wherein some cats are not protected yet others are completely resistant to identical challenge doses administered in an identical manner. It is our opinion that further, very fundamental studies of virus-host interactions and the mechanisms governing immunity to FIPV must be performed before guidelines for a realistic immunisation strategy can be sketched out.
